Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biostate for immune tolerance induction in paediatric haemophilia A with high‑titre FVIII inhibitors
2010-020113-85Phase 3Terminated
- Sponsor
- CSL Limited
- Start
- May 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of factor viii + von Willebrand factor in hemophilia A, sponsored by CSL Limited. Primary endpoint: Complete immune tolerance induction. Started May 2011; status: terminated.
02
Drugs
factor viii + von Willebrand factor
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2010-020113-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020113-85.